Loading
SEVILLA is a French-British randomised trial comparing ivonescimab, an antibody that blocks both PD-1 and the blood vessel signal VEGF, with FOLFOX chemotherapy as second-line treatment for bile duct and gallbladder cancer. University College London is the UK site.
SEVILLA (NCT06529718) is a randomised phase 2 run by UNICANCER at 42 sites in France and the United Kingdom, open since October 2025 with 72 patients planned and primary completion listed for August 2027. Eligible patients have histologically proven intrahepatic, perihilar or distal cholangiocarcinoma or gallbladder carcinoma (ampullary carcinoma excluded) that has progressed after first-line treatment, and are randomised to the PD-1 and VEGF bispecific antibody ivonescimab or to FOLFOX, the ABC-06 standard. The primary endpoint is progression-free survival. It is one of the first trials to test a bispecific immunotherapy against chemotherapy in second-line biliary cancer and gives UK patients with gallbladder cancer a randomised second-line option.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ivonescimab, Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, VEGF / VEGFR.
Shares UNICANCER, Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups).
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Bispecific antibodies.
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types).
Shares Ivonescimab, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Bispecific antibodies, Biliary tract cancer (all types).
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types).
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types).
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/